Blood Based Biomarker Test to Predict Major Cardiac Events

Cardiovascular BiomarkersPrevencio, Inc. has announced data published in The American Journal of Cardiology, on a new proteomic blood test that determines whether a person will have a heart attack, stroke, or other major adverse cardiac event (MACE) more accurately than the currently used clinical risk factors.  A total of 927 patient samples were analyzed from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study undergoing coronary angiography.

Read More

Inflammatory Cytokines as Potential Biomarker for Pain Intensity

Biomarkers for pain assessment are needed for more accurate pain therapy treatment in patients unable to reliably self-report their circumstances such as patients with dementia, intubated patients, and infants. The authors of a study recently published in Biomarkers in Medicine, Soluble intercellular adhesion molecule-1: a potential biomarker for pain intensity in chronic pain patients, hypothesized that pain intensity might be assessable using inflammatory molecules measurable in serum.

Read More

Human Cytokine Testing on Cell Culture Supernatant for SPHEROIDS project

3D Growth of Endothelial Cells During ISS Space Mission – The SPHEROIDS Project

The April 2017 issue of Biomaterials reports on an automated cell culture unit that was developed for the SpaceX CRS-ISS space mission that resulted in three dimensional growth of human endothelial cells in microgravity.

A spaceflight to the International Space Station, carried out in April – May 2016, included a study to examine endothelial cell (EC) behavior in respect to cellular proliferation and apoptosis under spaceflight conditions to examine the gravity dependency of EC tube formation.

Read More

Phase I Clinical Results from FR104, a mAb Specific to CD28

Researchers led by Bernard Vanove of OSE Immunotherapeutics report in the December 7, 2016 issue of the Journal of Immunology on the first-in-human study of FR1041. OSE and collaborators at the University of Nantes and Janssen conducted a detailed phase I evaluation of safety, pharmacokinetics, pharmacodynamics and potency of FR104 in healthy volunteers.

Read More

GDF-15 as a Possible Biomarker for Use and Dosing of Metformin in Type II Diabetes

Novel nonglycemic biomarker for metformin

The Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial delivers more insight on biomarkers that have potential to help treat patients with dysglycemia.1 Hertzel C. Gerstein and colleagues report Growth Differentiation Factor 15 as a novel biomarker for the use and dosing of metformin, in a study published in Diabetes Care last month.

Read More

Induced immune responses in monkeys alter with movement in social status

Social status can be used as predictor of life expectancy and overall health.  It is easy to conclude that this is a result of better diet, healthcare, and lack of external risk factors but, as a team of researchers reported in the November 25th issue of the journal Science, movement in social status in rhesus macaques influenced changes in immune system phenotypes.

Read More

IL-10 (AM0010) phase I trial offers novel mechanism for immune-oncology drugs in solid tumors

More commonly known as an inhibitory cytokine, high doses of IL-10 have been shown to lead to the activation and survival of antigen stimulated CD8 T cells. According to a study published in the Journal of Clinical Oncology, the investigators in this first-in-human, phase 1 clinical trial of IL-10 (AM0010), demonstrate antitumor activity and therapy tolerability in a pretreated population.  The primary endpoint of the study was to establish safety, tolerability and the maximum tolerated dose.  This goal appears to have been met, with a low incidence of adverse events, most of which were temporary or reversible.  The dose-escalation study was followed by a renal cell cancer dose-expansion cohort.

Read More
1 2 3 18